Celldex 治療公司
DE ˙ DB ˙ US15117B2025
€25.28 ↑0.78 (3.18%)
2026-06-04
分享價格
SecurityDE:TCE2 / Celldex Therapeutics, Inc.
InstitutionEversept Partners, LP
Latest Disclosed Ownership1,788,016 shares
Latest Disclosed Value $ 56,715,868
Eversept Partners, LP ownership in TCE2 / Celldex Therapeutics, Inc.

On May 15, 2026 - Eversept Partners, LP filed a 13F-HR form disclosing ownership of 1,788,016 shares of Celldex Therapeutics, Inc. (DE:TCE2) valued at $45,773,210 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,434,725 shares of Celldex Therapeutics, Inc.. This represents a change in shares of 24.62% during the quarter. The current value of the position is $45,415,606 USD.

Eversept Partners, LP has a history of taking positions in derivatives of the underlying security (TCE2) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:TCE2 / Celldex Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 1,788,016 353,291 24.62 56,716 45.55 2.9907
2026-02-17 2025-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 1,434,725 280,805 24.33 38,967 30.54 1.9636
2025-11-14 2025-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 1,153,920 315,184 37.58 29,852 74.89 2.0573
2025-08-14 2025-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 838,736 142,237 20.42 17,068 35.02 1.5699
2025-05-15 2025-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 696,499 -23,337 -3.24 12,641 -30.51 1.2838
2025-02-14 2024-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 719,836 154,934 27.43 18,190 -5.27 1.6148
2024-11-14 2024-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 564,902 -68,113 -10.76 19,201 -18.04 1.3153
2024-08-14 2024-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 633,015 -78,100 -10.98 23,428 -21.50 1.6043
2024-05-15 2024-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 711,115 -42,992 -5.70 29,845 -0.21 1.9910
2024-02-14 2023-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 754,107 165,964 28.22 29,908 84.78 2.6275
2023-11-14 2023-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 588,143 -197,597 -25.15 16,186 -39.29 1.3697
2023-11-08 2023-06-30 13F/A-1 CELLDEX THERAPEUTICS INC COM NEW 15117B202 785,740 96,064 13.93 26,660 7.44 2.2289
2023-08-14 2023-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 785,740 96,064 26,660 2.7595
2023-11-08 2023-03-31 13F/A-1 CELLDEX THERAPEUTICS INC COM NEW 15117B202 689,676 130,902 23.43 24,815 -0.36 1.7302
2023-05-15 2023-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 689,676 130,902 24,815 2.1650
2023-11-08 2022-12-31 13F/A-1 CELLDEX THERAPEUTICS INC COM NEW 15117B202 558,774 -67,598 -10.79 24,905 41.44 2.1816
2023-02-14 2022-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 558,774 -67,598 24,905 2.3020
2023-11-08 2022-09-30 13F/A-1 CELLDEX THERAPEUTICS INC COM NEW 15117B202 626,372 73,984 13.39 17,607 18.23 1.5269
2022-11-14 2022-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 626,372 624,456 17,607 1.7996
2023-11-08 2022-06-30 13F/A-1 CELLDEX THERAPEUTICS INC COM NEW 15117B202 552,388 -84,065 -13.21 14,892 -31.30 1.0593
2022-08-15 2022-06-30 13F CELLDEX THERAPEUTICS INC CALL 15117B902 1,916 1,916 2,454 0.2006
2022-08-15 2022-06-30 13F CELLDEX THERAPEUTICS INC PUT 15117B952 606 606 288 0.0235
2022-08-15 2022-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 552,388 14,892
2023-11-08 2022-03-31 13F/A-1 CELLDEX THERAPEUTICS INC COM NEW 15117B202 636,453 43,975 7.42 21,678 -5.31 1.6646
2022-05-16 2022-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 636,453 43,975 21,678 1.7880
2023-11-08 2021-12-31 13F/A-1 CELLDEX THERAPEUTICS INC COM NEW 15117B202 592,478 592,478 22,893 1.4630
2022-02-14 2021-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 592,478 592,478 22,893 1.6851
2023-11-08 2020-12-31 13F/A-2 CELLDEX THERAPEUTICS INC COM NEW 15117B202 0 -150,494 -100.00 0 -100.00
2023-11-08 2020-12-31 13F/A-1 CELLDEX THERAPEUTICS INC COM NEW 15117B202 0 -150,494 0
2021-02-16 2020-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 0 -150,494 0
2023-11-08 2020-09-30 13F/A-2 CELLDEX THERAPEUTICS INC COM NEW 15117B202 150,494 -562,204 -78.88 2,232 -75.92 0.4966
2020-11-13 2020-09-30 13F/A-1 CELLDEX THERAPEUTICS INC COM NEW 15117B202 150,494 -562,204 2,232 0.5020
2020-11-12 2020-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 712,698 0 9,265 1,495,804.8043
2023-11-08 2020-06-30 13F/A-1 CELLDEX THERAPEUTICS INC COM NEW 15117B202 712,698 712,698 9,265 1.2705
2020-08-13 2020-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 712,698 712,698 9,265 1.4958
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2023-11-08 2022-09-30 13F/A CELLDEX THERAPEUTICS INC COM NEW Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-11-08 2022-06-30 13F/A CELLDEX THERAPEUTICS INC COM NEW Call 191,600 5,166 n/a n/a n/a
2022-08-15 2022-06-30 13F CELLDEX THERAPEUTICS INC CALL 1,916 2,454 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2023-11-08 2022-09-30 13F/A CELLDEX THERAPEUTICS INC COM NEW Put 0 -100.00 0 -100.00 n/a n/a n/a
2023-11-08 2022-06-30 13F/A CELLDEX THERAPEUTICS INC COM NEW Put 60,600 1,634 n/a n/a n/a
2022-08-15 2022-06-30 13F CELLDEX THERAPEUTICS INC PUT 606 288 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.